Stay updated with breaking news from Abevmy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abevmy, co-developed by Biocon Biologics and Viatris, is a biosimilar to Roche’s Avastin (Bevacizumab) and has been approved by Health Canada across four oncology indications.
Biocon Biologics, Viatris get CHMP nod for Abevmy March 01, 2021 Kiran Mazumdar-Shaw, Chairperson, Biocon× Drug is a biologic therapy for metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer Biocon Biologics Ltd (a subsidiary of Biocon Ltd ) has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation of its biosimilar Bevacizumab, co-developed with Viatris, to be marketed as Abevmy (injection bevacizumab 100mg and 400mg...
Biocon Biologics and Viatris Inc receive CHMP nod for Abevmy®, a Biosimilar to Avastin® Bevacizumab Bangaluru, Mar 1 (UNI) Biocon Biologics Ltd, a subsidiary of Biocon Ltd, announced on Monday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of their biosimilar Bevacizumab, co-developed with Viatris, to be marketed as Abevmy®(injection bevacizumab 100mg and 400mg). A statement said that Abevmy® is a biosimilar to Roche’s Avastin®, prescribed for all indications includ...